… help health care professionals make treatment decisions. The summary included … of the individual VOLTAIRE trials. Biosimilars referencing adalimumab, a monoclonal antibody … were not significantly different between treatment groups. Serious infections were …

… modifying anti-rheumatic drugs had a substantially … factor (TNF)-α (infliximab, adalimumab, etanercept, golimumab, and certolizumab … dosage, duration, and treatment sequencing across biologic therapies … retrospective cohort study. PLOS Medicine. 2025;22(4). …

… Food and Drug Administration granted an interchangeable designation to YUFLYMA (adalimumab-aaty … provider. YUFLYMA is FDA approved for the treatment of patients with rheumatoid … the same indications for HUMIRA (adalimumab).  As we previously reported, YUFLYMA …

… 39;s petition to the FDA, calling on the agency to … in response to the European Medicines Agency's (EMA) … Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, … help bring down sky-high drug prices, President Donald Trump …

… , given their underrepresentation in clinical trials. “This study compared a large … a new biologic drug. The use of this medication was evaluated whether … after biologic treatment for psoriasis, particularly in those treated with adalimumab.” References …

… double-blind, placebo-controlled trial enrolled 221 patients with … medical meeting. The drug is also being investigated in Phase II trials … adalimumab), which is one of the world’s best-selling drugs … got US Food and Drug Administration (FDA) clearance in 2002. …

… patient access, particularly for costly treatments, and established a stronger overall … also addressed sustainability concerns, noting adalimumab biosimilars have a 28% market … concerns about whether the current drug pipeline is sufficient to provide …

… published in Clinical and Experimental Medicine.1 This review was … Anti-TNF-α agents (eg, infliximab, adalimumab) and their biosimilars are approved … vaccinations, and monitor throughout treatment. Innovative drug delivery systems are improving biologic …

… prior biologic agent use (adalimumab, golimumab, infliximab, vedolizumab, … . The epidemiology of drug treatment failure in rheumatoid arthritis … A, et al. Medication compliance and persistence: … for randomized controlled trials in inflammatory bowel …

… , “In addition, the FDA and EMA have intensified their … in the case of FDA, and these streamlined efforts … Cordavis private-label products, adalimumab biosimilars’ market share has … the Centers for Medicare & Medicaid Services publishes updated quarterly …